Sanofi has signed an $8bn revolving credit facility agreement under which it stands to make savings on its margin repayment obligations if it achieves specific sustainability targets.
Hitherto uncommon in the pharma industry, sustainable finance is gathering pace in the wider corporate world as national and supranational policymakers attempt to steer financial systems towards models